HBA1C
发表于 2025-3-21 17:14:32
书目名称Resistance to Proteasome Inhibitors in Cancer影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0828458<br><br> <br><br>书目名称Resistance to Proteasome Inhibitors in Cancer读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0828458<br><br> <br><br>
Biomarker
发表于 2025-3-21 22:55:29
Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resiercome resistance, e.g., by novel proteasome inhibitors and combinations of bortezomib with other chemotherapeutic drugs. Finally, an update is provided of the ongoing clinical trials investigating the potential benefits of proteasome inhibitors in acute leukemia.
IRK
发表于 2025-3-22 01:27:47
http://reply.papertrans.cn/83/8285/828458/828458_3.png
travail
发表于 2025-3-22 07:01:42
Resistance to Proteasome Inhibitors in Multiple Myeloma, bone destruction, anemia, hypercalcemia, and renal failure. Although MM remains incurable, a dramatic paradigm shift in the treatment of MM has occurred over the past decade through the introduction of novel agents, including the development of small molecule inhibitors targeting the proteasome. Am
愉快吗
发表于 2025-3-22 09:43:59
http://reply.papertrans.cn/83/8285/828458/828458_5.png
Wordlist
发表于 2025-3-22 15:35:09
http://reply.papertrans.cn/83/8285/828458/828458_6.png
多山
发表于 2025-3-22 21:06:12
http://reply.papertrans.cn/83/8285/828458/828458_7.png
Recess
发表于 2025-3-22 21:57:33
http://reply.papertrans.cn/83/8285/828458/828458_8.png
俗艳
发表于 2025-3-23 04:51:34
http://reply.papertrans.cn/83/8285/828458/828458_9.png
alleviate
发表于 2025-3-23 06:16:15
Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and Newthe in vitro sensitivity of HNSCC cells to proteasome inhibitors, clinical testing of bortezomib in HNSCC patients has encountered obstacles of inherent resistance and adverse toxicities. To combat these difficulties, current efforts are focused on developing strategies that co-target the proteasome